Drugmaker fined by Spanish regulators $10M for 'excessive price' of rare disease drug
A company that has been under the microscope for drug pricing before has found itself fined by Spanish regulators.
Leadiant Biosciences has been fined €10.3 million ($10.6 million) by the Spanish regulators Comisión Nacional de Los Mercados y la Competencia (CNMC), after a massive price hike of its chenodeoxycholic acid (CDCA) compound, which is used to treat the rare disease cerebrotendinous xanthomatosis (CTX).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
